Comparative Pharmacology
Head-to-head clinical analysis: FAZACLO ODT versus SEROQUEL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAZACLO ODT versus SEROQUEL XR.
FAZACLO ODT vs SEROQUEL XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clozapine is an atypical antipsychotic that antagonizes serotonin 5-HT2A and dopamine D2 receptors, with higher affinity for 5-HT2A. It also blocks muscarinic M1, histaminergic H1, and adrenergic α1 and α2 receptors.
SEROQUEL XR (quetiapine fumarate) is an atypical antipsychotic that acts as an antagonist at multiple neurotransmitter receptors: serotonin 5-HT1A and 5-HT2A, dopamine D1 and D2, histamine H1, and adrenergic α1 and α2 receptors. It also has partial agonist activity at 5-HT1A receptors. The therapeutic efficacy in schizophrenia and bipolar disorder is primarily attributed to dopamine D2 and serotonin 5-HT2A antagonism.
Clozapine (FAZACLO ODT) is an atypical antipsychotic. For schizophrenia, the typical starting dose is 12.5 mg orally once daily or twice daily, titrated by 25-50 mg/day to a target dose of 300-450 mg/day divided, up to a maximum of 900 mg/day. For treatment-resistant schizophrenia, the target dose is 300-450 mg/day, with doses above 500 mg/day requiring slower titration. The oral disintegrating tablet is taken sublingually or swallowed whole.
Initial: 300 mg orally once daily; may increase by 300 mg/day every 2-3 days. Target dose: 400-800 mg/day for schizophrenia; 300-600 mg/day for bipolar depression; 400-800 mg/day for acute mania. Maximum: 800 mg/day.
None Documented
None Documented
Terminal elimination half-life: 14 hours (range 6-26 hours) at steady state; increases with dose/duration. Context: Twice-daily dosing achieves steady state in 5-7 days.
Terminal elimination half-life: approximately 7 hours (range 6-9 hours) for the extended-release formulation. Clinical context: once-daily dosing achieves steady-state within 2 days.
Renal: 50% as metabolites (30% conjugated, 20% desmethylclozapine), 30% as unchanged; Fecal: 30% (biliary/fecal elimination of metabolites).
Primarily hepatic; 70-73% excreted in urine as metabolites (mostly inactive), 20-24% in feces. Less than 1% excreted unchanged in urine.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic